ArticleOncotarget2017

ERRF sensitizes ERBB2-positive breast cancer cells to lapatinib treatment likely by attenuating MCL1 and ERBB2 expression.

Leilei Qi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.